Incidencia de eventos arrítmicos y mortalidad en la población portadora de un desfibrilador automático implantable en España

Abstract

The implantable cardioverter defibrillator (ICD) is a leading therapy in preventing sudden cardiac death (SCD). For the past 20 years, several randomized clinical trials have demonstrated the benefit that high-risk patients obtain after an ICD implantation. The ICD therapy is related to a 20% reduction in all-cause death, mainly driven by a 54% relative reduction in the risk of SCD, among heart failure (HF) patients with reduced left ventricle ejection fraction (LVEF). However, there are populations that were under represented inclinical trials. On the other hand, data extracted from the extended follow-up of randomized clinical trials demonstrated that the ICD benefit is maintained after long-term follow-up. Moreover, patients at higher risk of an ICD shock have also worse prognosis. As the ICD therapy is related to some adverse events it is necessary to understand the characteristics of the Spanish population receiving an ICD and to describe prognosis after long-term follow-up. The analysis of the Spanish population receiving an ICD, stratified according to the underlying heart disease and ICD indication, will be useful to compare the incidence of arrhythmic events, ICD interventions and all-cause death, as well as to describe patients´ subgroups that obtain more benefit after an ICD implant...